Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07446101
PHASE1

A Study of Mirikizumab Solution (LY3074828) in Healthy Participants

Sponsor: Eli Lilly and Company

View on ClinicalTrials.gov

Summary

The main purpose of this study is to assess the safety and tolerability of mirikizumab (LY3074828) solution formulation administered as a single injection compared with two injections under the skin in healthy participants. Blood tests will be performed to investigate how the body processes the study drug. For each participant, the study will last about 15 weeks.

Official title: An Adaptive Two-Stage Bioequivalence Study of Subcutaneous Injections of Mirikizumab Solution in Healthy Participants

Key Details

Gender

All

Age Range

18 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

450

Start Date

2026-03

Completion Date

2027-02

Last Updated

2026-03-19

Healthy Volunteers

Yes

Conditions

Interventions

DRUG

Mirikizumab

Administered SC

Locations (5)

Fortrea Clinical Research Unit

Daytona Beach, Florida, United States

Axis Clinicals LLC

Dilworth, Minnesota, United States

Fortrea Clinical Research Unit

Dallas, Texas, United States

Worldwide Clinical Trials, Inc.

San Antonio, Texas, United States

Fortrea Clinical Research Unit

Madison, Wisconsin, United States